Possibilities of therapy for patients with sensorineural hearing loss at the present stage

Cover Page

Cite item

Full Text

Abstract

Sensorineural hearing loss is one of the common diseases and it represents an urgent problem of otorhinolaryngology. The most complex and significant issues are acute and sudden sensorineural hearing loss. Every year, the number of patients suffering from this pathology is steadily growing. The increase in the number of cases of sensorineural hearing loss is associated with a number of socio-medical aspects of human life at the present stage - the growth of somatic and immune pathology, frequent stresses, high noise and vibration levels, regular use of headphones, environmental degradation and the influence of other adverse factors. The widespread use of audiometric research methods contributes to a more accurate diagnosis of impaired sound in patients of various age groups, which also affects the epidemiological data. In connection with the above, the study of modern treatment options for patients with sensorineural hearing loss is an urgent problem of clinical medicine.

About the authors

Valeriy M. Svistushkin

Sechenov First Moscow State Medical University (Sechenov University), Moscow

Email: svvm3@yandex.ru
д-р мед. наук, проф., зав. каф. болезней уха, горла и носа Moscow, Russia

Ani B. Ordyan

Sechenov First Moscow State Medical University (Sechenov University), Moscow

аспирант каф. болезней уха, горла и носа Moscow, Russia

Galina N. Nikiforova

Sechenov First Moscow State Medical University (Sechenov University), Moscow

д-р мед. наук, проф. каф. болезней уха, горла и носа Moscow, Russia

Svetlana V. Morozova

Sechenov First Moscow State Medical University (Sechenov University), Moscow

д-р мед. наук, проф., каф. болезней уха, горла и носа Moscow, Russia

Vladimir F. Gergiev

Sechenov First Moscow State Medical University (Sechenov University), Moscow

ассистент каф. болезней уха, горла и носа Moscow, Russia

References

  1. Глухота и потеря слуха. Всемирная организация здравоохранения, 2019. https://www.who.int/ru/news-room/fact-sheets/detail/deafness-and-hearing-loss
  2. Клинические рекомендации. Сенсоневральная тугоухость у взрослых. 2016. Национальная медицинская ассоциация оториноларингологов. http://pro-audiologia.ru/images/pdf/tugouhost-u-vzroslyh.pdf
  3. Schreiber BE, Agrup C, Haskard DO, Luxon LM. Sudden sensorineural hearing loss. Lancet 2010; 375 (9721): 120311. doi: 10.1016/S0140-6736(09)62071-7
  4. Парфенов В.А., Антоненко ЛМ Нейросенсорная тугоухость в неврологической практике. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (2): 10-4.
  5. Kuhn M, Heman-Ackah SE, Shaikh JA, Roehm PC. Sudden Sensorineural Hearing Loss: A Review of Diagnosis, Treatment, and Prognosis. Trends Amplif 2011; 15 (3): 91-105. doi: 10.1177/1084713811408349
  6. Shirwany NA, Seidman MD, Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol 1998; 19 (2): 230-5.
  7. Cvorovic L, Eric D, Probst R, Hegemann S. Prognostic model for predicting hearing recovery in idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008; 29 (4): 464-9. doi: 10.1097/MAO.0b013e31816fdcb4
  8. Fitzgerald DC, McGuire JF. Intratympanic steroids for idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 2007; 116 (4): 253-6. doi: 10.1177/000348940711600405
  9. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109 (7 Pt 2): 1-17. doi: 10.1097/00005537-199907001-00001
  10. Slattery WH, Fisher LM, Iqbal Z et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005; 133 (2): 251-9. doi: 10.1016/j.otohns.2005.05.015
  11. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005; 26 (5): 878-81. doi: 10.1097/01.mao.0000185052.07513.5a
  12. Bird PA, Begg EJ, Zhang M et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007; 28 (8): 1124-30. doi: 10.1097/MAO.0b013e31815aee21
  13. Косяков С.Я., Атанесян А.Г., Гуненков А.В. Местная терапия острой сенсоневральной тугоухости путем интра-тимпанального введения стероидов. Вестн. оториноларингологии. 2012; 3: 74-8.
  14. Masoumi E, Dabiri S, Ashtiani MTK et al. Methylprednisolone versus dexamethasone for control of vertigo in patients with definite Meniere’s disease. Iran J Otorhinolaryngol 2017; 29 (95): 341-46.
  15. Berjis N, Soheilipour S, Musavi A, Hashemi S. Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv Biomed Res 2016; 5: 111. doi: 10.4103/22779175.184277
  16. Balough BJ. Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss After Failure of Systemic Therapy. Yearb Otolaryngol Neck Surg 2008.
  17. Seggas I, Koltsidopoulos P, Bibas A et al. Intratympanic steroid therapy for sudden hearing loss: A review of the literature. Otol Neurotol 2011; 32 (1): 29-35. doi: 10.1097/mao.0b013e3181f7aba3
  18. El Sabbagh NG, Sewitch MJ, Bezdjian A, Daniel SJ. Intratympanic dexamethasone in sudden sensorineural hearing loss: A systematic review and meta-analysis. Laryngoscope 2017; 127 (8): 1897-908. doi: 10.1002/lary.26394
  19. Haynes DS, O'Malley M, Cohen S. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007; 117 (1): 3-15. doi: 10.1097/01.mlg.0000245058.11866.15
  20. Alexander TH, Harris JP, Nguyen QT, Vorasubin N. Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL. Otol Neurotol 2015; 36 (8): 1321-7. doi: 10.1097/MAO.0000000000000834
  21. Kiliq R., Safak MA, Oguz H et al. Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol 2007; 28 (3): 312-6. doi: 10.1097/MAO.0b013e31802fba7a
  22. Bhandari A, Jain S. Early intratympanic methylprednisolone in sudden SNHL: A frequency-wise analysis. Indian J Otolaryngol Head Neck Surg 2019; 71 (3): 390-95. doi: 10.1007/s12070-019-01582-5
  23. Dai Y, Lu L, Hou J et al. Intratympanic methylprednisolone perfusion as a salvage treatment for profound idiopathic sudden sensorineural hearing loss. J Laryngol Otol 2017; 131 (5): 404-10. doi: 10.1017/S0022215117000548
  24. Dallan I, De Vito A, Fatto B et al. Intratympanic methylprednisolone in refractory sudden hearing loss: A 27-patient case series with univariate and multivariate analysis. Otol Neurotol 2010; 31 (1): 25-30. doi: 10.1097/MAO.0b013e3181c34f18
  25. Tarkan 0, Dagkiran M, Surmelioglu 0 et al. Intratympanic methylprednisolone versus dexamethasone for the primary treatment of idiopathic sudden sensorineural hearing loss. J Int Adv Otol 2018; 14 (3): 451-55. doi: 10.5152/iao.2018.4871
  26. Yang J, Huang L, Shi J et al. The effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010; 24 (13): 594-7.
  27. Topf MC, Hsu DW, Adams DR et al. Rate of tympanic membrane perforation after intratympanic steroid injection. Am J Otolaryngol 2017; 38 (1): 21-5. doi: 10.1016/j.amjoto.2016.09.004
  28. Park SH, Park C, Seo JY et al. How long should patients remain in the supine treatment position after intratympanic dexamethasone injection? Laryngoscope 2014; 124 (12): 2807-10. doi: 10.1002/lary.24872

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies